Rocket Pharmaceuticals develops curative gene‑therapy treatments for rare, devastating genetic diseases by leveraging a dual platform strategy—ex vivo lentiviral vectors for hematopoietic targets and in vivo adeno‑associated viral vectors for systemic delivery. Their pipeline focuses on high‑unmet‑need bone‑marrow‑derived and cardiovascular disorders, selecting the optimal technology for each indication to deliver durable, disease‑modifying outcomes.
Funding
$175M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare, devastating genetic diseases often have no effective treatments, leaving them and their families without options to address the underlying cause of their conditions.
Solution
Rocket Pharmaceuticals develops gene therapy cures that target the root cause of these diseases. By employing a flexible, multi‑platform strategy—using ex vivo lentiviral (LV) vectors for hematopoietic targets and in vivo adeno‑associated viral (AAV) vectors for systemic delivery—the company selects the optimal technology for each indication. Their pipeline focuses on high‑unmet‑need disorders affecting bone‑marrow‑derived and cardiovascular systems. Preclinical and clinical programs aim to deliver durable, curative outcomes that eliminate the genetic defect rather than merely managing symptoms.
Target Audience
Primary customers are patients and caregivers affected by rare genetic diseases, as well as clinicians and healthcare systems seeking curative gene‑therapy options for these conditions.
Features
- Dual platform capability: ex vivo LV for precise gene correction in patient‑derived cells and in vivo AAV for direct tissue targeting
- Platform selection based on disease biology to maximize efficacy and safety
- Pipeline includes therapies for rare bone‑marrow‑derived and cardiovascular genetic disorders
- Integrated preclinical and clinical development workflow leveraging decades of biotech experience
- Commitment to patient‑centric development, incorporating caregiver input and community support